BRAF Inhibition: Bridge or Boost to T-cell Therapy?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30824585.
- Also identified by DOI 10.1158/1078-0432.CCR-19-0286 and PMC identifier 6497532.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The concept of treatment-refractory disease has evolved as checkpoint modulation has changed the therapeutic landscape for patients with metastatic melanoma. Developing meaningful salvage strategies will involve the exploration of combination therapies and new immunotherapeutics, including adoptive transfer of tumor-infiltrating lymphocytes or other T-cell-based therapy.<i>See related article by Atay et al., p. 2783</i>.
Medical subject headings
- Melanoma
- Proto-Oncogene Proteins B-raf